20 Jan 2020 – Positive update on the development of new XF-platform drug formulations

Collaboration with MedPharm Ltd. delivers data profiling new XF‐platform drug formulations as potential treatments for dermal and ocular infections.

New formulations support a growing pipeline alongside lead drug asset, XF-73, currently in Phase 2b development with data anticipated in mid-2020.

Please see Destiny Pharma press release here